One Novel Full-Length Gene PKI Related to Human Glioma

祁震宇,王中,惠国桢,李瑶,顾少华,谢毅

DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2009.09.006

2009-01-01

Abstract:oma,and it could provide a new way to gene therapy of glioma.

What problem does this paper attempt to address?

[Expression and Characterizations of a Novel Full-Length Gene PKIbeta Related to Human Glioma].

Zhen-Yu Qi,Guo-Zhen Hui,Yao Li,Shao-Hua Gu,Yi Xie

DOI: https://doi.org/10.3321/j.issn:0376-2491.2008.25.013

2008-01-01

Abstract:OBJECTIVE:To obtain differentially expressed genes related to human glioma using cDNA microarray and to characterization of one novel full-length gene.METHOD:Four samples of human glioma samples, 1 fetal brain tissue sample, and 2 normal brain tissue samples were used to extract the total RNA, and the mRNA was used to make probes. After hybridization and washing procedure, the products of hybridization were scanned using computer system. One gene, named 436F11 clone, was subsequently analyzed by Northern blotting, bioinformatics, and protein expression.RESULT:Fifteen differentially expressed new genes related to human glioma were obtained through four times of hybridization and scanning. Northern blotting confirmed that over-expression of 436F11 gene in the normal human brain tissue and low-expression in the human glioma tissues. The analysis of BLASTn and BLASTx showed that the clone of 436F11 was a novel full-length gene coding 78 amino acids of protein with a theoretical relative molecular weight of 8648 and an isoelectric point of 4.69 and that it was 60% identical to mouse PKIbeta amino acid, so it was called human PKIbeta gene. After it was transfected into Escherichia coli, higher-expressed protein of PKIbeta was obtained which yielded a major clear band on an SDS-PAGE gel after purification. The products obtained from amino acid sequencing and molecular weight detection were exactly the same as the products performed by bioinformatic analysis.CONCLUSION:cDNA microarray technology can be successfully applied to identify differentially expressed genes. PKIbeta may be a novel full-length gene related to human glioma and may provide a new way to gene therapy of glioma.
Bioinformatics of One Novel Full-Length Gene Related to Human Glioma

QI Zhen-yu,WANG Zhong,LI Yao,GU Shao-hua,XIE Yi

DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2011.06.040

2011-01-01

Abstract:Objective To obtain differentially expressed genes related to human glioma using cDNA microarray and study the characterization of one novel full-length gene. Methods Total RNA was extracted from human glioma tissues and normal brain tissues, and mRNA was used to make probes. After hybridization and washing procedure, the results of hybridization were scanned using computer system. One gene named 681F05 clone was subsequently analyzed by northern blotting and bioinformatic analysis. Results We obtained 15 differentially expressed genes to human glioma through 4 times hybridizations and scanning. Northern blotting analysis confirmed 681F05 clone was down-regulated in human brain tissue and up-regulated in human glioma tissues. The analysis of BLASTn and BLASTx showed that clone 681F05 isolated was two cDNA clones encoding two novel proteins which showed 52% and 72% identity to the cyclophilin isoform 10 of C. Elgans, respectively. Sequence analysis revealed these two cDNA clones were two different splicing variants of a novel cycophilin-like gene ( PPIL3a and PPIL3b). Conclusion cDNA microarray technology can be successfully applied to identify differentially expressed genes. The novel fulllength gene of human PPIL3 may be correlated with tumorigenesis of human glioma.
Gene Therapy with HSV1-sr39TK/GCV Exhibits a Stronger Therapeutic Efficacy Than HSV1-TK/GCV in Rat C6 Glioma Cells

Lei-qing Li,Fang Shen,Xiao-yan Xu,Hong Zhang,Xiao-feng Yang,Wei-guo Liu

DOI: https://doi.org/10.1155/2013/951343

2013-01-01

Abstract:Although the combination of herpes simplex virus type 1 (HSV-1) thymidine kinase (TK) with ganciclovir (GCV) has been shown as a promising suicide gene treatment strategy for glioma, the almost immunodepressive dose of GCV required for its adequatein vivoefficacy has hampered its further clinical application. Therefore, In order to reduce the GCV dose required, we aim to compare the therapeutic efficacy of HSV1-sr39TK, an HSV1-TK mutant with increased GCV prodrug catalytic activity, with wildtype TK in C6 glioma cells. Accordingly, rat C6 glioma cells were first transfected with pCDNA-TK and pCDNA-sr39TK, respectively, and the gene transfection efficacy was verified by immunocytochemistry and western blot analysis. Then thein vivosensitivity of these transfected C6-TK and C6-sr39TK cells to GCV was determined by 3-(4,5)-dimethylthiahiazo-(-z-y1)-3,5-di-phenytetrazoliumromide (MTT) colorimetric assay and Hoechst-propidium iodide (PI) staining. Finally, a subcutaneously C6 xenograft tumor model was established in the nude mice to test thein vitroefficacy of TK/GCV gene therapy. Our results showed that, as compared with wildtype TK, HSV1-sr39TK/GCV demonstrated a stronger therapeutic efficacy against C6 glioma bothin vitroandin vivo, which, by reducing the required GCV dose, might warrant its future use in the treatment of glioma under clinical setting.
Isolation and expression of one novel full-length gene related to human glioma

祁震宇,惠国桢,李瑶,顾少华,谢毅

DOI: https://doi.org/10.3321/j.issn:1001-9030.2008.04.024

2008-01-01

Abstract:Objective To obtain differentially expressed genes related to human glioma using cDNA microarray and the characterization of one novel full-length gene.Methods Total RNA was extracted from human glioma tissues and normal brain tissues.and mRNA was used to make probes.After hybridization and washing procedures,the results of hybridization were scanned using computer system.One gene named 681F05 clone was subsequently analyzed by northern blot,in situ hybridization and bioinformatics.Resuits Fifteen differentially expressed genes to human glioma were obtained through four times hybridizations and scanning.Northern blot analysis confirmed 681F05 clone was low-expressed in human brain tissue and over-expressed in human glioma tissues.This result was iust the same as the result of in situ hybridization.The analysis of BLASTn and BLASTx showed that clone 681F05 we isolated was two cDNA clones encoding two novel proteins which showed 52% and 72% identity to the cyclophilin isoform 10 of C.Elgans,respectively.Sequence analysis revealed these two cDNA clones were two different splicing variants of a novel cycophilin-like gene(PPIL3a and PPIL3b).Conclusion cDNA microarray technology can be successfully applied to identify differentially expressed genes.The novel full-length gene of human PPIL3 may be correlated with the genesis of human glioma.
Isolation of one novel full-length gene related to human giioma and its expression in vitro

QI Zhen-yu,HUI Guo-zhen,LI Yao,祁震宇,惠国桢,李瑶,周宗祥,顾少华,应康,谢毅

2006-01-01

Abstract:Objective To obtain differentially expressed genes related to human glioma using cDNA microarray and the characterization of one novel full-length gene. Methods Total RNA was extracted from human glioma tissues and normal brain tissues, and mRNA was used to make probes. After hybridization and washing procedure, the results of hybridization were scanned using computer system. One gene named 507E08 clone was subsequently analyzed by Northern blot, bioinformatics, protein expression and amino acid sequencing. Results Fifteen differentially expressed genes to human glioma were obtained through 4 times hybridizations and scanning. Northern blot analysis confirmed 507E08 clone was low-expression in human brain tissue and over-expression in human glioma tissues. This result was just the same as that of in situ hybridization. The analysis of BLASTn and BLASTx showed that clone 507E08 was novel full-length gene coding 203 amino acid of protein, and itwas called human ribosomal protein 14.22 gene. After expression in E. coli, protein yielded a major band of apparent molecular mass 22×103 on an SDS-PAGE gel. Amino acid sequencing analysis of the recombinant L14.22 protein indicated that 15 amino acid sequences of N-termination was exactly same as the 15 amino acid residues of N-termination of L14.22 protein sequence. Conclusion cDNA microarray technology can be successfully applied to identify differentially expressed genes. The novel full-length gene of human ribosomal protein 14.22 may be correlate with pathogenesis of human glioma.
Isolation of One Novel Full-Length Gene Related to Human Glioma

Z Qi,G Hui,Y Li

DOI: https://doi.org/10.3760/j:issn:0376-2491.2001.18.011

2001-01-01

Abstract:OBJECTIVES:To obtain differentially expressed genes related to human glioma using cDNA microarray and make a preliminary study of one novel full-length gene.METHODS:Total RNA was extracted from human glioma tissues and normal brain tissues, and mRNA was used to make probes. After hybridization and washing procedure, the results of hybridization were scanned using computer system. One gene named 507E08 clone was subsequently analyzed by northern blotting, in situ hybridization, bioinformatics and radiation hybridization.RESULTS:Fifteen differentially expressed novel genes related to human glioma were obtained through four times of hybridization and scanning. Northern blotting and in situ hybridization confirmed that 507E08 clone was lowly expressed in normal human brain tissue and over-expressed in human glioma tissue. BLASTn and BLASTx analysis showed that the clone 507E08 was a novel full-length gene with the length of 2002 bp. This gene, called human ribosomal protein 14.22 gene, codes 203 amino acids and is located on chromosome 14 between D14S1066 Marker and D14S265 Marker.CONCLUSION:cDNA microarray technology can be successfully applied to identify differentially expressed genes with small amount of specimen, high quality, high speed, and high sensitivity. The novel full-length human ribosomal protein 14.22 gene may correlate with formation of human glioma.
Isolation of One Novel Full-Length Gene PPIL-3 Related to Human Glioma and Characterization of This Protein

QI Zhen-yu,HUI Guo-zhen,LI Yao,GU Shao-hua,XIE Yi

DOI: https://doi.org/10.3760/cma.j.issn.1001-2346.2009.03.009

2009-01-01

Abstract:Objective To obtain differentially expressed genes related to human glioma using cDNA microarray and the characterization of one novel full-length gene. Method Total RNA was extracted from human glioma tissues and normal brain tissues,and mRNA was used to make probes. After hybridization and washing procedure, the results of hybridization were scanned using computer system. One gene named 681F05 clone was subsequently analyzed by northern blot, four times hybridizations and scanning. Northern blot analysis confirmed 681F05 clone was low-exprbioinformatics and protein expression. Results We obtain 15 differentially expressed genes to human glioma througession in human brain tissue and over-expression inhuman glioma tissues. The analysis of BLASTn and BLASTx showed that clone 681F05 we isolated was two cDNA clones encoding two novel proteins which show 52% and 72% identity to the eyelophilin isoform 10 of C. Elgans,respectively. Sequence analysis revealed these two cDNA clones are two different splicing variants of a novel cycophilin-like gene (PPIL3a and PPIL3b). In E. Coli. ,we got the more high-expressed fusion protein of PPIL3a combined with GST and PPIL3b combined with GST. Activity analysis of the recombinant PPIL3b protein shows that PPIL3b protein has nuclease activity. The nuclease activity of PPIL3b protein is stimulated by Ca2+ and/or Mg2+ and inhibited by K+/Na+. Conclusions We show that cDNA microarray technology can be successfully applied to identify differentially expressed genes. The novel full-length gene of human PPIL3 maybe correlate with forming human glioma.
Delivery Sirna With A Novel Gene Vector For Glioma Therapy By Targeting Gli1

Peizhi Zhou,Yue Cao,Xiaoxiao Liu,Ting Yu,Qian Xu,Chao You,Xiang Gao,Yuquan Wei

DOI: https://doi.org/10.2147/IJN.S164364

IF: 7.033

2018-01-01

International Journal of Nanomedicine

Abstract:Background: Gene therapy has recently shown considerable clinical benefit in cancer therapy during the past few years, and the application of this choice in cancer treatments is increasing continually. Gli1 is an ideal candidate target for cancer gene therapy and is important for tumorigenesis.Methods: In this study, we developed a novel gene delivery system with a self-assembly method by using a 1,2-dioleoyl-3-trimethylammonium-propane and methoxy poly (ethylene glycol)-poly(lactide) copolymer (DMP), with zeta potential of 32.7 mV and measuring 35.6 nm. The effect of this delivery system was tested in vitro and in vivo.Results: DMP showed good performance in delivering siRNA to glioma cells in vitro with high transfection performance (98%). Moreover, DMP-Gli1si shows a satisfactory antiglioma effect via induction of cell apoptosis and cell growth inhibition in vitro. Furthermore, for subcutaneous tumor-bearing mice, treatment with the DMP-Gli1si complex significantly inhibited tumor growth by inhibiting Gli1 protein expression, promoting apoptosis, and reducing proliferation.Conclusion: The complex of Gli1 siRNA and DMP may potentially play an important role as a new drug in the clinical treatment of gliomas.
Isolation of Novel Differentially Expressed Genes Related to Human Glioma Using CDNA Microarray and Characterizations of Two Novel Full-length Genes

Zhen-Yu Qi,Yao Li,Kang Ying,Chao-Qun Wu,Rong Tang,Zong-Xiang Zhou,Zhong-Ping Chen,Guo-Zhen Hui,Yi Xie

DOI: https://doi.org/10.1023/a:1015079705841

2002-01-01

Journal of Neuro-Oncology

Abstract:Identification of the genes that are differentially expressed between brain tumor and normal brain tissues is important for understanding the molecular basis of these nerve system tumors and for defining possible targets for therapeutic intervention. This investigation is intended to obtain differentially expressed genes related to human glioma using cDNA microarray. Total RNA was extracted from human glioma specimens and normal brain tissues, and mRNA was obtained by oligotex chromatography. The cDNA microarray contains 4366 novel cDNA clones. The results of hybridization were scanned using computer system. Two genes selected from the results of cDNA microarray hybridization were subsequently analyzed by bio-informatic approach, Northern blot, in situ hybridization and radiation hybridization. We demonstrated that at a differentially expressed ration of two to three times, 15 cDNA clones were considered differentially expressed. Two novel full-length genes were selected for further investigation, one named human PKIβ gene (clone 436F11, GenBankTM with accession number: AF225513) was over-expressed in normal brain tissues and the other named human ribosomal protein L14.22 gene (clone 507E08, GenBankTM with accession number: AF329277) was over-expressed in gliomas. Furthermore, the 436F11 gene was located on 6q21–q23 between the D6S304 and D6S2156 markers, while the 507E08 gene was located between the D14S1066 and D14S265 markers. We realized that cDNA microarray technology can be successfully applied to identify differentially expressed genes in human glioma. This approach is superior to routine representational difference analysis, suppression subtractive hybridization and Northern blot for detection and isolation of differentially expressed genes in different tissues. At present, we have discovered two novel full-length genes related to human glioma and their characterizations have been partially clarified.
Report of Two Novel Full-Length Genes Related to Human Glioma and Their Chromosome Mapping

祁震宇,惠国桢,王兆,吴海,应康,顾少华,谢毅

DOI: https://doi.org/10.3969/j.issn.1671-2897.2002.02.015

2002-01-01

Abstract:Objective To report two novel full-length genes related to human glioma and their chromosome mapping. Methods Two genes related to human glioma were sequenced and analyzed by basic local alignment search tool ( BLAT) , and subsequently further analyzed by Northern blot and radiation hybridization (RH). Results They were novel full-length genes, and their accession numbers in Genebank were AF225513 and AF329277. It was confirmed by Northern blot analysis that the 436 F11 clone was over-expressed in human brain tissues but under-expressed in human glioma tissues, and the result of the 507 E08 was just the reverse. The 436 F11 gene was located on 6q21-q23 between the D6S304 Marker and the D6S2156 Marker, and the 507 E08 gene was located on chromosome 14 between the D14S1066 Marker and the D14S265 Marker. Conclusion The two genes, related to human glioma and located on their chromosomes, are two novel full-length genes. They will open a new way for gene therapy of gliomas.
A Novel Dual Pi3k Alpha/Mtor Inhibitor Pi-103 with High Antitumor Activity in Non-Small Cell Lung Cancer Cells

Zu-Quan Zou,Xiao-Hong Zhang,Feng Wang,Qi-Jun Shen,Jin Xu,Li-Na Zhang,Wen-Hua Xing,Ren-Jie Zhuo,Duo Li

DOI: https://doi.org/10.3892/ijmm_00000212

IF: 5.314

2009-01-01

International Journal of Molecular Medicine

Abstract:PI-103, the first synthetic multitargeted compound which simultaneously inhibits PI31K alpha and mammalian target of rapamycin (mTOR) shows high antitumor activity in glioma xenografts. In the present study, clear antitumor activity was observed with PI-103 treatment in two gefitinib-resistant non-small cell lung cancer (NSCLC) cell lines, A549 and H460, by simultaneously inhibiting p70s6k phosporylation and Akt phosphorylation in response to mTOR inhibition. In addition, H460 cells with activating mutations of PIK3CA were more sensitive to PI-103 than A549 cells with wild-type PIK3CA. PI-103 was found to inhibit growth by causing GO-G, arrest in A549 and H460 cells. Western blotting showed that PI-103 induced down-regulation of cyclin D1 and E1 and simultaneously up-regulated p21 and p27, associated with arrest in the G(0)-G(1) phase of the cell cycle. Furthermore, p53, the tumor suppressor which transcriptionally regulates p21, was also upregulated with PI-103 treatment. Collectively, our results suggest that multitargeted intervention is the most effective tumor therapy, and the cooperative blockade of PI3K alpha and mTOR with PI-103 shows promise for treating gefitinib-resistant NSCLC.
Relation of peptidyl-prolyi isomerase 1 and Nanog expressions in human gliomas

Shengyuan Ni,Chaoshi Niu,Yang Yang,Xiangyu Zhang

DOI: https://doi.org/10.3760/cma.j.issn.1671-8925.2015.03.003

2015-01-01

Abstract:Objective To obsevre the peptidyl-prolyi isomerase 1 (PIN1) and Nanog expreesions in glioma tissues and the effect of PIN1 inhibitor polyiso-butylene (PiB) on their expressions and U87 cell proliferation.Methods Eighty-four glioma samples (15 with WHO graded Ⅱ,27 with WHO graded Ⅲ and 42 with WHO graded Ⅳ),collected in our hospital from March 2013 to August 2014,were chosen in our study; their expressions of PIN1 and Nanog were detected by immunohistochemical staining; U87 glioblastoma cell lines were cultured; 0.2,0.5,1.0 and 2.0 μg/mL PiB was given to the cells for 24 and 48 h,and then,MTT assay was employed to detect the inhibited effect and inhibition ratio was calculated; 1.0 μmol/L PiB group (U87 cells treated with 1.0 μmol/L PiB for 24 h) and control group (U87 cells without any treatment) were chosen,immunofluorescence staining was used to detect the PIN1 and Nanog protein expressions,and real time-PCR and Western blotting were employed to observe the mRNA and protein expressions of PIN1 and Nanog.Results The positive protein expression rate of PIN1 and Nanog in gliomas of different grades (WHO graded Ⅱ,Ⅲ and Ⅳ) was significantly different (P＜0.05):the higher the malignancy grade,the higher the rate of positive protein expression of PIN1 and Nanog.MTT assay indicated that PiB could inhibit the cell proliferation in dose-and concentration-dependent manners; as compared with the control group,1.0 μmol/L PiB group had significantly decreased percentages of PIN1+,Nanog+ and PIN1+/Nanog+ cells (P＜0.05); the mRNA PIN1 expression quantity in the control group and 1.0 μmol/L PiB group was 1.82±0.03 and 0.94±0.20,and that of Nanog was 1.47±0.04 and 0.82±0.19,with significant differences (P＜0.05); the protein PIN1 expression quantity in the control group and 1.0 μmol/L PiB group was 2.96±0.05 and 1.15±0.26,and that of Nanog was 1.52±0.16 and 0.75±0.05,with significant differences (P＜0.05).Conclusion PIN1 and Nanog play important roles in the pathogenesis of human gliomas and are related to the glioma malignancy; PIN1 may participate in the regulation of Nanog,and there is a pathway between the two genes; the glioma cell proliferation ability is suppressed by down-regulating the PIN1-Nanog expression.
A Novel Full-Length Gene of Human Ribosomal Protein L14-22 Related to Human Glioma

Qi Zhen-Yu,Hui Guo-zhen,Li Yao,Zhou Zong-xiang,Gu Shao-hua,Xie Yi

DOI: https://doi.org/10.1097/00029330-200608020-00007

IF: 6.133

2006-01-01

Chinese Medical Journal

Abstract:BACKGROUND:This study was undertaken to obtain differentially expressed genes related to human glioma by cDNA microarray and the characterization of a novel full-length gene.METHODS:Total RNA was extracted form human glioma and normal brain tissue, and mRNA was used as a probe. The results of hybridization procedure were scanned with the computer system. The gene named 507E08 cone was subsequently analyzed by northern blot, bioinformatic approach, and protein expression.RESULTS:Fifteen differentially expressed genes were obtained from human glioma by hybridization and scanning for four times. Northern blot analysis confirmed that the 507E08 clone was low expressed in human brain tissue and over expressed in human glioma tissues. The analysis of BLASTn and BLASTx showed that the 507E08 clone was a novel full-length gene, which codes 203 amino acid of protein and is called human ribosomal protein 14.22 gene. The nucleotide sequence had been submitted to the GenBank with the accession number of AF329277. After expression in E. coli., protein yielded a major band of apparent molecular mass 22 kDa on an SDS-PAGE gel.CONCLUSIONS:cDNA microarray technology can be successfully used to identify differentially expressed genes. The novel full-length gene of human ribosomal protein 13.22 may be correlated with the development of human glioma.
PT109, a novel multi-kinase inhibitor suppresses glioblastoma multiforme through cell reprogramming: Involvement of PTBP1/PKM1/2 pathway

Yang Yang,Yalin Tu,Junfeng Lu,Qiuhe Chen,Zeyu Zhu,Weijia Peng,Wenbo Zhu,Shijun Wen,Ji Zhang,Wei Yin,Rongbiao Pi

DOI: https://doi.org/10.1016/j.ejphar.2022.174837

IF: 5.195

2022-04-01

European Journal of Pharmacology

Abstract:Glioblastoma multiforme (GBM) is the most prevalent type and lethal form of primary malignant brain tumor, accounting for about 40-50% of intracranial tumors and without effective treatments now. Cell reprogramming is one of the emerging treatment approaches for GBM, which can reprogram glioblastomas into non-tumor cells to achieve therapeutic effects. However, anti-GBM drugs through reprogramming can only provide limited symptom relief, and cannot completely cure GBM. Here we showed that PT109, a novel multi-kinase inhibitor, suppressed GBM's proliferation, colony formation, migration and reprogramed GBM into oligodendrocytes. Analysis of quantitative proteomics data after PT109 administration of human GBM cells showed significant influence of energy metabolism, cell cycle, and immune system processes of GBM-associated protein. Metabolomics analysis showed that PT109 improved the aerobic respiration process in glioma cells. Meanwhile, we found that PT109 could significantly increase the ratio of Pyruvate kinase M1/2 (PKM1/2) by reducing the level of polypyrimidine tract-binding protein 1 (PTBP1). Altogether, this work developed a novel anti-GBM small molecule PT109, which reprogramed GBM into oligodendrocytes and changed the metabolic pattern of GBM through the PTBP1/PKM1/2 pathway, providing a new strategy for the development of anti-glioma drugs.

pharmacology & pharmacy
Effect of protein kinase N1 on the biological behavior of human glioma

HAO Yu-bing,ZHANG An-ling,WANG Hu,WANG Guang-xiu,GAO Zhao,JIA Zhi-fan

DOI: https://doi.org/10.3969/j.issn.1672-6731.2020.12.009

2020-01-01

Chinese Journal of Contemporary Neurology and Neurosurgery

Abstract:Objective To study the expression of protein kinase N1 (PKN1) in glioma and its influence on the biological behavior of glioma cells. Methods The expression of PKN1 gene was verified via GEPIA database, and LN229, U87 and A172 gliomas cells were detected by Western blotting. A172 cells were transfected with negative control sequence (siRNA⁃NC group) and PKN1 small interference RNA (siRNA) sequence (siRNA⁃PKN1 group). CCK⁃8 assay, flow cytometry, scratch assay and Transwell assay were applied to detect proliferation, apoptosis rate, migration ability and invasion ability, respectively. Results Analysis of GEPIA database showed that the expression of PKN1 mRNA in glioblastoma tissues (163 cases) was significantly higher than that in nontumorous brain tissues (207 cases, P < 0.05). Western blotting showed that the relative expression of PKN1 protein in A172 cells was higher than that in U87 cells (t = 3.096, P = 0.036) and LN229 cells (t = 8.994, P = 0.000). The proliferation ability of A172 cells in siRNA⁃PKN1 group was lower than that in siRNA⁃NC group at day 3-6 after PKN1 gene was knocked down (t = 3.275, P = 0.031; t = 5.949, P = 0.004; t = 10.430, P = 0.000; t = 6.645, P = 0.003). The scratch healing rate of A172 cells in both groups increased in different degree over time (F = 249.993, P = 0.000). After PKN1 gene was knocked down, both the scratch healing rate (F = 97.811, P = 0.000) and the invasion cells number (t = 5.840, P = 0.004) of A172 cells were lower than that of siRNA ⁃ NC group, while the apoptosis rate of A172 cells was higher than that of siRNA⁃NC group (t = 5.461, P = 0.006). Conclusions The expression of PKN1 mRNA in glioma was higher than that in nontumorous brain tissue, and knockout of PKN1 gene could inhibit the proliferation, migration and invasion of tumor cells, and induce the apoptosis of tumor cells. DOI：10.3969/j.issn.1672⁃6731.2020.12.009
A Novel Defined Pyroptosis-Related Gene Signature for Predicting Prognosis and Treatment of Glioma

Zhihao Yang,Zhigang Chen,Yu Wang,Zhiwei Wang,Deran Zhang,Xiaoyu Yue,Yinfei Zheng,Lianxin Li,Erbao Bian,Bing Zhao

DOI: https://doi.org/10.3389/fonc.2022.717926

IF: 4.7

2022-03-31

Frontiers in Oncology

Abstract:Pyroptosis, a form of programmed cell death, that plays a significant role in the occurrence and progression of tumors, has been frequently investigated recently. However, the prognostic significance and therapeutic value of pyroptosis in glioma remain undetermined. In this research, we revealed the relationship of pyroptosis-related genes to glioma by analyzing whole transcriptome data from The Cancer Genome Atlas (TCGA) dataset serving as the training set and the Chinese Glioma Genome Atlas (CGGA) dataset serving as the validation set. We identified two subgroups of glioma patients with disparate prognostic and clinical features by performing consensus clustering analysis on nineteen pyroptosis-related genes that were differentially expressed between glioma and normal brain tissues. We further derived a risk signature, using eleven pyroptosis-related genes, that was demonstrated to be an independent prognostic factor for glioma. Furthermore, we used Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) to implement functional analysis of our gene set, and the results were closely related to immune and inflammatory responses in accordance with the characteristics of pyroptosis. Moreover, Gene Set Enrichment Analysis (GSEA) results showed that that the high-risk group exhibited enriched characteristics of malignant tumors in accordance with its poor prognosis. Next, we analyzed different immune cell infiltration between the two risk groups using ssGSEA. Finally, CASP1 was identified as a core gene, so we subsequently selected an inhibitor targeting CASP1 and simulated molecular docking. In addition, the inhibitory effect of belnacasan on glioma was verified at the cellular level. In conclusion, pyroptosis-related genes are of great significance for performing prognostic stratification and developing treatment strategies for glioma.

oncology
Progress of the Study of PCNA and Ki-67 in Brain Glioma

诸静其,施诚仁,金惠明

DOI: https://doi.org/10.3969/j.issn.1674-8115.2004.10.025

2004-01-01

Abstract:Glioma is a common tumor of brain. With development of molecular biology techniques, proliferating kinetics of the tumor cells is recognized further clinically. Proliferating cell nuclear antigen and Ki-67 are both markers which can reflect the proliferatve activity of the cells. They can evaluate the proliferative status of the brain glioma on the level of molecular biology. This method is easier and more objective than pathological grading. It has significant value in analysis and judgement of the growth and differentiation of the glioma. Also it is a useful factor in the choice of a clinical treatment plan and analysis of the prognosis. But the accuracy of the two markers need to be confirmed by further studies. So, in order to evaluate the prognosis of the patients with gliomas synthetically, we still should combine age,location of the tumor, pathological grading and other markers together.
Cdna Microarray in Isolation of Novel Differentially Expressed Genes Related to Human Glioma and Clone of a Novel Full-Length Gene.

ZY Qi,GZ Hui,Y Li,ZX Zhou,SH Gu,K Ying,Y Xie

2005-01-01

Abstract:BACKGROUND:This investigation was undertaken to obtain differentially expressed genes related to human glioma using cDNA microarray and the characterization of one novel full-length gene.METHODS:Total RNA was extracted from human glioma tissues and normal brain tissues, and mRNA was used to make probes. After hybridization and washing, the results were scanned using a computer system. The gene named 681F05 clone was an expressed gene to human glioma through four-time hybridization and scanning. Subsequently northern blot analysis was performed by northern blot, 5'RACE and bioinformatics.RESULTS:Fifteen differentially expressed genes to human glioma were obtained through four-time hybridization and scanning. Northern blot analysis confirmed that 681F05 clone was low-expressed in human brain tissues and over-expressed in human glioma tissues. The analysis of BLASTn and BLASTx showed that 681F05 clone is two cDNA clones encoding two novel proteins that are highly identified to the cyclophilin isoform 10 of C. Elgans, respectively. Sequence analysis revealed the two cDNA clones are two different splicing variants of a novel cycophilin-like gene (PPIL3a and PPIL3b).CONCLUSIONS:cDNA microarray technology can be successfully used to identify differentially expressed genes. The novel full-length gene of human PPIL3 may be correlated with the formation of human glioma.
Efficient Inhibition of Human Glioma Development by RNA Interference-Mediated Silencing of PAK5

Xuefeng Gu,Ce Wang,Xuefeng Wang,Guoda Ma,You Li,Lili Cui,Yanyan Chen,Bin Zhao,Keshen Li

DOI: https://doi.org/10.7150/ijbs.9193

2015-01-01

International Journal of Biological Sciences

Abstract:Glioma is the most common type of primary intracranial tumor and is highly lethal due to its pathogenetic location, high invasiveness, and poor prognosis. Even combined surgery and chemoradiotherapy do not effectively rescue glioma patients. Molecular target therapy is considered a safe and promising therapy for glioma. The identification of a novel, effective target protein in gliomas is of great interest. We found that PAK5 was highly expressed in the tumor tissues of glioma patients and human glioma cell lines. We then used a lentivirus-delivered short hairpin RNA to stably silence PAK5 expression in glioma cells and explore its influence. The results showed that the inhibition of PAK5 reduced cell viability and delayed the cell cycle at the G0/G1 phase in the glioma cells with PAK5 high expression. In addition, silencing PAK5 expression in U87 cells weakened their colony formation ability and in vivo tumorigenesis ability. Further studies demonstrated that PAK5 inhibition led to an increase in cleaved caspase 3 and a decrease in β-catenin. In conclusion, our results suggest that the inhibition of PAK5 by RNA interference might efficiently suppress tumor development of glioma cells with PAK5 high expression. This finding provides a novel, promising therapeutic target for glioma treatment.

biochemistry & molecular biology
Expression and Clinical Significance of Integrin Β1 Gene in Human Glioams

章翔,吴景文,郭衍,付洛安,高大宽

DOI: https://doi.org/10.3321/j.issn:1000-2790.2003.07.020

2001-01-01

Abstract:Objective To detect the expression of integrin β1 gene in humangliomas and analyze its clinical significance.Methods The expression of integrin β1 gene in 53 pieces glioma was detected by immunohistochemical and hybridization technique in situ.The patients were followed and their prognosis was compared.Results Integrin β1 positive rate of immunohistochmistry in gliomas of grade Ⅰ to Ⅳ was 36.3%,38.5%,72.2%and 81.8% respectively.Integrin β1 positive rate in gliomas of grade Ⅲ and Ⅳ was higher than that of grade Ⅰand Ⅱ(P<0.05).The integrin β1 mRNA expression in gliomas is coincide with its protein expression.The prognosis was worse and the survival time was shorter for the patient with higher expression of integrin β1.Conclusion The higher expression of integrin β1 was correlated with the lower differentation and higher invasiveness of gliomas.And integrin β1 may be a good indicator of jubging the prognosis of gliomas patient.

One Novel Full-Length Gene PKI Related to Human Glioma

[Expression and Characterizations of a Novel Full-Length Gene PKIbeta Related to Human Glioma].

Bioinformatics of One Novel Full-Length Gene Related to Human Glioma

Gene Therapy with HSV1-sr39TK/GCV Exhibits a Stronger Therapeutic Efficacy Than HSV1-TK/GCV in Rat C6 Glioma Cells

Isolation and expression of one novel full-length gene related to human glioma

Isolation of one novel full-length gene related to human giioma and its expression in vitro

Isolation of One Novel Full-Length Gene Related to Human Glioma

Isolation of One Novel Full-Length Gene PPIL-3 Related to Human Glioma and Characterization of This Protein

Delivery Sirna With A Novel Gene Vector For Glioma Therapy By Targeting Gli1

Isolation of Novel Differentially Expressed Genes Related to Human Glioma Using CDNA Microarray and Characterizations of Two Novel Full-length Genes

Report of Two Novel Full-Length Genes Related to Human Glioma and Their Chromosome Mapping

A Novel Dual Pi3k Alpha/Mtor Inhibitor Pi-103 with High Antitumor Activity in Non-Small Cell Lung Cancer Cells

Relation of peptidyl-prolyi isomerase 1 and Nanog expressions in human gliomas

A Novel Full-Length Gene of Human Ribosomal Protein L14-22 Related to Human Glioma

PT109, a novel multi-kinase inhibitor suppresses glioblastoma multiforme through cell reprogramming: Involvement of PTBP1/PKM1/2 pathway

Effect of protein kinase N1 on the biological behavior of human glioma

A Novel Defined Pyroptosis-Related Gene Signature for Predicting Prognosis and Treatment of Glioma

Progress of the Study of PCNA and Ki-67 in Brain Glioma

Cdna Microarray in Isolation of Novel Differentially Expressed Genes Related to Human Glioma and Clone of a Novel Full-Length Gene.

Efficient Inhibition of Human Glioma Development by RNA Interference-Mediated Silencing of PAK5

Expression and Clinical Significance of Integrin Β1 Gene in Human Glioams